Fusion Pharmaceuticals racks up $25 mln Series A
Hamilton, Ontario-based Fusion Pharmaceuticals, a newly formed biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, has closed $25 million in Series A financing. Johnson & Johnson Innovation – JJDC Inc led the round with participation from HealthCap, TPG Biotech, Genesys Capital and FACIT.
23 February 2017•1 min read
